Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 12:45 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 673–696 of 3,557 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: NSCLC (Non-small Cell Lung Carcinoma) Clear all
Active, not recruiting Phase 1Phase 2 Interventional

Trabedersen (OT-101) With Pembrolizumab for Newly Diagnosed Advanced NSCLC and Positive PD-L1

NCT06579196
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Trabedersen, Pembrolizumab
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 15, 2026, 12:45 PM EDT
Completed Phase 1 Interventional

A Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Cancer

NCT02391480
View directory record Official record
Conditions
Cancer, Breast Cancer, Non-Small Cell Lung Cancer, Acute Myeloid Leukemia (AML), Multiple Myeloma, Prostate Cancer, Small Cell Lung Cancer, Non-Hodgkins Lymphoma
Interventions
ABBV-075, Venetoclax
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
10
States / cities
Scottsdale, Arizona • Duarte, California • Sacramento, California + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2019 · Synced Oct 15, 2026, 12:45 PM EDT
Recruiting Phase 1 Interventional

Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer

NCT03819296
View directory record Official record
Conditions
Clinical Stage 0 Cutaneous Melanoma AJCC v8, Clinical Stage I Cutaneous Melanoma AJCC v8, Clinical Stage IA Cutaneous Melanoma AJCC v8, Clinical Stage IB Cutaneous Melanoma AJCC v8, Clinical Stage II Cutaneous Melanoma AJCC v8, Clinical Stage IIA Cutaneous Melanoma AJCC v8, Clinical Stage IIB Cutaneous Melanoma AJCC v8, Clinical Stage IIC Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Colitis, Lung Non-Small Cell Carcinoma, Malignant Genitourinary System Neoplasm, Malignant Solid Neoplasm, Pathologic Stage 0 Cutaneous Melanoma AJCC v8, Pathologic Stage I Cutaneous Melanoma AJCC v8, Pathologic Stage IA Cutaneous Melanoma AJCC v8, Pathologic Stage IB Cutaneous Melanoma AJCC v8, Pathologic Stage II Cutaneous Melanoma AJCC v8, Pathologic Stage IIA Cutaneous Melanoma AJCC v8, Pathologic Stage IIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIC Cutaneous Melanoma AJCC v8, Pathologic Stage III Cutaneous Melanoma AJCC v8, Pathologic Stage IIIA Cutaneous Melanoma AJCC v8, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8, Pathologic Stage IV Cutaneous Melanoma AJCC v8, Stage 0 Lung Cancer AJCC v8, Stage I Lung Cancer AJCC v8, Stage IA1 Lung Cancer AJCC v8, Stage IA2 Lung Cancer AJCC v8, Stage IA3 Lung Cancer AJCC v8, Stage IB Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8, Stage IIA Lung Cancer AJCC v8, Stage IIB Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions
Best Practice, Biospecimen Collection, Endoscopic Procedure, Fecal Microbiota Transplantation, Infliximab, Laboratory Biomarker Analysis, Prednisone, Vedolizumab
Other · Procedure · Biological + 1 more
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Oct 15, 2026, 12:45 PM EDT
Completed Phase 1 Interventional

Temsirolimus and Radiation for Non-Small Cell Lung Cancer

NCT00796796
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Temsirolimus, Radiation therapy
Drug · Radiation
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 11, 2013 · Synced Oct 15, 2026, 12:45 PM EDT
Active, not recruiting Phase 2 Interventional Results available

A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) Over Intravenous Pembrolizumab (MK-3475) Formulation in Multiple Tumor Types (MK-3475A-F11)

NCT06099782
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, Renal Cell Carcinoma, Melanoma
Interventions
Pembrolizumab (+) Berahyaluronidase alfa, Pembrolizumab
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
8
States / cities
Alexander City, Alabama • Anchorage, Alaska • Springdale, Arkansas + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Oct 15, 2026, 12:45 PM EDT
Completed Phase 2 Interventional

A Study of Local Ablative Therapy (LAT) in People With Non-Small Cell Lung Cancer (NSCLC)

NCT05429320
View directory record Official record
Conditions
Non-small Cell Lung Cancer, Metastatic Non Small Cell Lung Cancer, Nsclc, NSCLC Stage IV, Minimal Residual Disease, Non Small Cell Lung Cancer Metastatic
Interventions
Local ablative therapy, Blood collection to assess for ctDNA
Procedure · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
9
States / cities
Hartford, Connecticut • Miami, Florida • Basking Ridge, New Jersey + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2026 · Synced Oct 15, 2026, 12:45 PM EDT
Terminated Not applicable Interventional

Biofeedback Training in Patients With Advanced Lung Cancer - A Pilot Study

NCT01685346
View directory record Official record
Conditions
Advanced (Stage IV) Non-small Cell Lung Cancer (NSCLC)
Interventions
biofeedback-mediated stress management (BFSM)
Behavioral
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 10, 2015 · Synced Oct 15, 2026, 12:45 PM EDT
Completed Phase 3 Interventional

Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Previously Untreated Advanced or Metastatic Squamous Non-Small Cell Lung Cancer

NCT02106546
View directory record Official record
Conditions
Squamous Non-Small Cell Lung Cancer
Interventions
Carboplatin, Veliparib, Paclitaxel, Placebo to veliparib
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 99 Years
Enrollment
970 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
38
States / cities
Jonesboro, Arkansas • Los Angeles, California • Aurora, Colorado + 30 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2020 · Synced Oct 15, 2026, 12:45 PM EDT
Active, not recruiting Phase 2 Interventional

The Study of NC318 Alone or in Combination With Pembrolizumab in Patients With Advanced Non-small Cell Lung Cancer

NCT04699123
View directory record Official record
Conditions
Advanced Non-small Cell Lung Cancer
Interventions
NC318 800 mg, NC318 400 mg, Pembrolizumab
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 15, 2026, 12:45 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC

NCT04995523
View directory record Official record
Conditions
Non-Small-Cell Lung Carcinoma
Interventions
AZD2936
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
3
States / cities
Chicago, Illinois • Rochester, Minnesota • Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 15, 2026, 12:45 PM EDT
Completed Phase 1 Interventional

Gemcitabine, Carboplatin, and Lenalidomide for Treatment of Advanced/Metastatic Urothelial Cancer and Other Solid Tumors

NCT01352962
View directory record Official record
Conditions
Urethral Neoplasms, Neoplasms, Urethral, Cancer of the Urethra, Urethral Cancer
Interventions
Gemcitabine, Carboplatin, Lenalidomide
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 15, 2026, 12:45 PM EDT
Completed Phase 1 Interventional

A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors

NCT03289962
View directory record Official record
Conditions
Melanoma, Non-Small Cell Lung Cancer, Bladder Cancer, Colorectal Cancer, Triple Negative Breast Cancer, Renal Cancer, Head and Neck Cancer, Other Solid Cancers
Interventions
Autogene cevumeran, Atezolizumab
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
273 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
15
States / cities
Scottsdale, Arizona • Los Angeles, California • San Francisco, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Oct 15, 2026, 12:45 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors

NCT07749586
View directory record Official record
Conditions
Advanced Solid Tumor
Interventions
ARV-6723, Pembrolizumab, SOC
Drug
Lead sponsor
Arvinas Inc.
Industry
Eligibility
18 Years and older
Enrollment
499 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
4
States / cities
New York, New York • Huntersville, North Carolina • San Antonio, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 15, 2026, 12:45 PM EDT
Completed Phase 2 Interventional Results available

Dose/ Schedule Finding Trial of Romiplostim for Chemotherapy-Induced Thrombocytopenia (CIT) in Non-Small Cell Lung Cancer (NSCLC)

NCT00413283
View directory record Official record
Conditions
Lung Cancer, Chemotherapy-Induced Thrombocytopenia, Non-Small Cell Lung Cancer, Cancer, Lung Neoplasms, Oncology, Solid Tumors, Thrombocytopenia
Interventions
Romiplostim, Placebo, Gemcitabine, Carboplatin, Cisplatin
Biological · Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
51
States / cities
Glendale, Arizona • Anaheim, California • Los Angeles, California + 22 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2013 · Synced Oct 15, 2026, 12:45 PM EDT
Terminated Phase 2 Interventional

GRN-1201 With Pembrolizumab in Subjects With Metastatic PD-L1+ NSCLC

NCT03417882
View directory record Official record
Conditions
Metastatic NSCLC
Interventions
GRN-1201 + Pembrolizumab
Biological
Lead sponsor
BrightPath Biotherapeutics
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
11
States / cities
Orange, California • Aurora, Colorado • Orlando, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2023 · Synced Oct 15, 2026, 12:45 PM EDT
Active, not recruiting Phase 1 Interventional

ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer

NCT05650879
View directory record Official record
Conditions
HER2 Mutant Non-small Cell Lung Cancer, HER2-positive Metastatic Breast Cancer, HER2 Gene Mutation, HER2 Amplification
Interventions
ELVN-002, Fam-Trastuzumab Deruxtecan-Nxki, Trastuzumab emtansine
Drug
Lead sponsor
Enliven Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
5
States / cities
Aurora, Colorado • Orlando, Florida • Plantation, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2025 · Synced Oct 15, 2026, 12:45 PM EDT
Recruiting Phase 2 Interventional

Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers

NCT04410796
View directory record Official record
Conditions
Metastatic Non-small Cell Lung Cancer
Interventions
Osimertinib, Carboplatin, Pemetrexed
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
571 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
18
States / cities
Sacramento, California • San Francisco, California • Tampa, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 15, 2026, 12:45 PM EDT
Completed Phase 2 Interventional Results available

Stereotactic Body Radiation Therapy in Treating Patients With Stage I or Stage II Non-Small Cell Lung Cancer That Can Be Removed By Surgery

NCT00551369
View directory record Official record
Conditions
Lung Cancer
Interventions
SBRT
Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2018
U.S. locations
19
States / cities
Birmingham, Alabama • Berkeley, California • Carmichael, California + 16 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2019 · Synced Oct 15, 2026, 12:45 PM EDT
Completed No phase listed Observational

Utility of Routine Cervical Mediastinoscopy in Clinical Stage I Non-Small Cell Lung Cancer (NSCLC)

NCT01146366
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Not listed
Lead sponsor
Jennifer Bell
Other
Eligibility
18 Years and older
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
4
States / cities
Atlanta, Georgia • St Louis, Missouri • Chapel Hill, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2014 · Synced Oct 15, 2026, 12:45 PM EDT
Terminated Phase 1 Interventional

TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid Tumors

NCT02650635
View directory record Official record
Conditions
Colorectal Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Recurrent Breast Carcinoma, Recurrent Colorectal Carcinoma, Recurrent Melanoma of the Skin, Recurrent Non-Small Cell Lung Carcinoma, Recurrent Pancreatic Carcinoma, Recurrent Renal Cell Carcinoma, Solid Neoplasm, Stage IV Breast Cancer, Stage IV Non-Small Cell Lung Cancer, Stage IV Renal Cell Cancer, Stage IV Skin Melanoma, Stage IVA Colorectal Cancer, Stage IVA Pancreatic Cancer, Stage IVB Colorectal Cancer, Stage IVB Pancreatic Cancer
Interventions
Cyclophosphamide, Laboratory Biomarker Analysis, Pegfilgrastim, Pharmacological Study, TLR8 Agonist VTX-2337
Drug · Other · Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 5, 2018 · Synced Oct 15, 2026, 12:45 PM EDT
Completed Phase 1 Interventional

Radiation Therapy in Treating Patients With Stage I Non-Small Cell Lung Cancer And Lung Dysfunction

NCT00009789
View directory record Official record
Conditions
Lung Cancer
Interventions
accelerated conformational radiotherapy
Radiation
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2010
U.S. locations
20
States / cities
Fort Lauderdale, Florida • Hollywood, Florida • Jupiter, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2016 · Synced Oct 15, 2026, 12:45 PM EDT
Completed Not applicable Interventional

Supportive Care Intervention (ROAR-LCT) for Patients With Stage IIIA, IIIB, and IV Lung Cancer, ROAR-LCT Trial

NCT05339022
View directory record Official record
Conditions
Advanced Lung Non-Small Cell Carcinoma, Advanced Lung Small Cell Carcinoma, Extensive Stage Lung Small Cell Carcinoma, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8, Unresectable Lung Non-Small Cell Carcinoma, Unresectable Lung Small Cell Carcinoma
Interventions
Best Practice, Exercise Intervention, Physical Therapy, Quality-of-Life Assessment, Questionnaire Administration, Relaxation Therapy
Other · Procedure
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
60 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 21, 2025 · Synced Oct 15, 2026, 12:45 PM EDT
Completed Phase 2 Interventional

Nitrocamptothecin in Treating Patients With Recurrent Non-small Cell Lung Cancer

NCT00005872
View directory record Official record
Conditions
Lung Cancer
Interventions
rubitecan
Drug
Lead sponsor
Astex Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2004
U.S. locations
1
States / cities
Dublin, California
Source: ClinicalTrials.gov public record
Updated Dec 4, 2013 · Synced Oct 15, 2026, 12:45 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Phase 1/2 Study of Combination Immunotherapy and Messenger Ribonucleic Acid (mRNA) Vaccine in Subjects With NSCLC

NCT03164772
View directory record Official record
Conditions
Metastatic Non-small Cell Lung Cancer, NSCLC
Interventions
Durvalumab, Tremelimumab, BI 1361849, PharmaJet Tropis® device
Drug · Biological · Device
Lead sponsor
Ludwig Institute for Cancer Research
Other
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
5
States / cities
Gilbert, Arizona • Tampa, Florida • Detroit, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2022 · Synced Oct 15, 2026, 12:45 PM EDT